Navigation Links
Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
Date:8/12/2009

DURHAM, N.C., Aug. 12 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has filed its annual report on Form 10-K for the fiscal year ended April 30, 2009. In addition to being available from the Securities And Exchange Commission website at www.SEC.gov, the 10-K can be downloaded from the company website at www.oxybiomed.com via the SEC Filings link on the Investors page.

For the year ended April 30, 2009, the company incurred a loss of $33,218,840 compared to a loss of $6,721,168 for the previous fiscal year. The increase in net loss is attributable primarily to an increase of approximately $5 million in general and administrative expenses and a one-time, non-cash charge of $24,856,041 for interest expense. The Form 10-K should be read for full details of these expenses.

"During the fiscal year we converted most of the five-year convertible debentures, reflected as long term debt on our balance sheet, to equity. In doing so, we eliminated all of the related interest obligation and the related discounts on this debt. When we eliminated our obligation we had to take a non-cash charge against income in the amount of the interest we would have had to pay had this conversion not occurred," said Chris Stern, company chairman and CEO. "Most of that finance charge comes from financings from before 2008 that had drastic warrant clauses. Now, with these obligations eliminated, our balance sheet is much stronger. Combined with the recent financing agreement with Vatea Fund, we are in a financial position where we believe we have the working capital necessary to fund our operations and development pipeline and sustain the company
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
5. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
9. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
10. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
11. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  The registration deadline has ... Financial Officers (ABFO) 2013 National Conference, the premier conference ... May 28-31 at the Hilton San Diego Bayfront. ... this year,s conference and want to make sure as ... said Brandi Roberts , Chief Financial ...
(Date:5/16/2013)... FL (PRWEB) May 16, 2013 As the ... to showcase their favorite Spring looks. While most make a ... season. Unfortunately, many women find the warmer weather mixes makeup ... women cope with the onset of acne during warmer months, ... from female acne treatment users the best ways to deter ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... Analysis: Therapeutic Proteins – Biosimilars, Biobetters ...   Product ... The new Competitive Intelligence Report Therapeutic ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – The ... and Future Opportunities (13-004) , With barriers to ... cells market continues to increase. In this study, BioInformatics ... how satisfied scientists are with commercially available primary cells, ... ,  , Additionally, terminally differentiated cells can be ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Mich., Jan. 23, 2012  A recent Van Andel Research Institute ... the molecular structure and function of an essential plant hormone ... and might ultimately lead to the development of new drugs ... builds on earlier work by the same team of investigators ...
... Jan. 23, 2012 Aethlon Medical, Inc. ... therapeutic filtration devices to address infectious disease, cancer ... has established an Extracorporeal Therapy Scientific Advisory Board ... and other therapies developed from the Aethlon ADAPT™ ...
... NEW YORK, Jan. 23, 2012   NeoStem, Inc. (NYSE ... international biopharmaceutical company with a focus on cell-based therapeutic development, ... for its PreSERVE Phase 2 clinical trial for ... infarction patients, and the President of its subsidiary, Progenitor ...
Cached Biology Technology:Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 2Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 4
(Date:5/16/2013)... to a fast food restaurant had a higher body ... from fast food, according to researchers at The University ... was particularly strong among those with a lower income. ... American Journal of Public Health indicates higher ... restaurant, and among lower-income African-Americans, the density, or number, ...
(Date:5/16/2013)... the cellular layer lining the body,s blood vessels, ... nanometers in thickness, this super-tenuous structure routinely withstands ... to create a unique and highly dynamic barrier ... from the body,s circulatory system. , It,s also ... be physically breached to enable immune cells ...
(Date:5/16/2013)... has discovered an ancient extinct creature with ,scissor hand-like, ... honour of his favourite movie star. , The ... (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ancestor ... Johnny Depp for his starring role as Edward Scissorhands ... an unfinished creation, who has scissors for hands. ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Actor Johnny Depp immortalized in ancient fossil find 2
... long and very cold but the winter of 2009-2010 ... and the re-introduced wild Przewalski,s horse population crashed dramatically. ... Veterinary Medicine, Vienna have used spatially explicit loss statistics, ... into the effect of a catastrophic climate event on ...
... New research has found that elderly people with higher ... their blood had better performance on mental acuity tests and ... while "junk food" diets produced just the opposite result. ... specifically measure a wide range of blood nutrient levels instead ...
... research suggests that China,s impressive feat of cutting Beijing,s pollution ... some help from Mother Nature. Rain just at the beginning ... the effort needed to clean up the skies, scientists found. ... widely implemented than in 2008 if pollution levels are to ...
Cached Biology News:Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 2Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 3Diet, nutrient levels linked to cognitive ability, brain shrinkage 2Weather deserves medal for clean air during 2008 Olympics 2
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at the ... is intended for use as an internal ... (PGE2) by GC- or LC-mass spectrometry. PGE2 ... of arachidonic acid and one of the ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Request Info...
Biology Products: